Cardiotech steps up CardioPass development:
This article was originally published in Clinica
Cardiotech International is pressing ahead with a preclinical research programme to assess its synthetic coronary artery bypass graft after early study data confirmed that the product had acceptable handling characteristics and potential for clinical use. The CardioPass graft is manufactured from the company's ChronoFlex biodurable polyurethane polymer. Cardiotech predicts that animal studies of the graft could start early next year, followed by human trials around mid-2003. The firm Woburn, Massachusetts, firm estimates that heart bypass surgery represents a market opportunity of $1.5 billion for synthetic grafts.